Literature DB >> 26135559

GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.

Brooke E Howitt1, Megan M Emori, Ronny Drapkin, Cynthia Gaspar, Justine A Barletta, Marisa R Nucci, W Glenn McCluggage, Esther Oliva, Michelle S Hirsch.   

Abstract

GATA3 is a transcription factor critical for embryogenesis, development, and cell differentiation. Recent studies have suggested that GATA3 is a sensitive and relatively specific biomarker for urothelial and breast carcinomas, with most Müllerian carcinomas being negative. We investigated GATA3 expression in mesonephric/Wolffian remnants and tumors in the female genital tract. A western blot was performed to assess specificity for the GATA3 antibody. GATA3 immunohistochemistry was performed on 59 formalin-fixed paraffin-embedded mesonephric samples, including 17 mesonephric remnants (MR; 11 cervical and 6 fallopian tube), 15 mesonephric hyperplasias, 21 mesonephric carcinomas, and 6 female adnexal tumors of probable Wolffian origin. Thirty conventional endocervical adenocarcinomas (ENDO-CA), 9 gastric-type cervical adenocarcinomas, and 165 endometrial adenocarcinomas (EM-CA) were also evaluated. GATA3 nuclear intensity and extent of staining was evaluated. The western blot revealed GATA3 expression in seminal vesicle and cell lines derived from breast and urothelial carcinomas, but not in other cell lines including ovarian, cervical, and endometrial cancers. All cervical MRs and mesonephric hyperplasias, 5/6 (83%) fallopian tube MRs, and 20/21 (95%) mesonephric carcinomas were GATA3 positive, although with great variability in both intensity (weak to strong) and extent (1+ to 3+) of staining. Only 1/6 (17%) female adnexal tumors of probable Wolffian origin showed weak multifocal staining. One of 30 (3%) usual-type ENDO-CAs and 3/165 EM-CAs exhibited weak-moderate GATA3 immunoreactivity; all gastric-type cervical adenocarcinomas were negative. GATA3 is a highly sensitive and specific marker for mesonephric lesions in the lower genital tract; however, its utility in the upper genital tract may be more limited. In addition, GATA3 can aid in distinguishing lower genital mesonephric lesions from usual-type and gastric-type ENDO-CAs and uterine EM-CAs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26135559     DOI: 10.1097/PAS.0000000000000471

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

1.  Uterine Paramesonephric Cysts in Sprague-Dawley Rats from National Toxicology Program Studies.

Authors:  Daven N Jackson-Humbles; John Curtis Seely; Ronald A Herbert; David E Malarkey; Barry S McIntyre; Paul M Foster; Darlene Dixon
Journal:  Toxicol Pathol       Date:  2018-04-29       Impact factor: 1.902

Review 2.  The central role of the pathologist in the management of patients with cervical cancer: ESGO/ESTRO/ESP guidelines.

Authors:  Maria Rosaria Raspollini; Sigurd F Lax; W Glenn McCluggage
Journal:  Virchows Arch       Date:  2018-05-24       Impact factor: 4.064

3.  Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.

Authors:  Simona Stolnicu; Iulia Barsan; Lien Hoang; Prusha Patel; Luis Chiriboga; Cristina Terinte; Anna Pesci; Sarit Aviel-Ronen; Takako Kiyokawa; Isabel Alvarado-Cabrero; Malcolm C Pike; Esther Oliva; Kay J Park; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394

Review 4.  [Ectopic tissue of the female genital tract].

Authors:  F Otterbach; D Schmidt
Journal:  Pathologe       Date:  2018-09       Impact factor: 1.011

5.  Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis.

Authors:  Marcela S Cavalcanti; Anne M Schultheis; Caleb Ho; Lu Wang; Deborah F DeLair; Britta Weigelt; Ginger Gardner; Stuart M Lichtman; Meera Hameed; Kay J Park
Journal:  Int J Gynecol Pathol       Date:  2017-01       Impact factor: 2.762

6.  International Endocervical Adenocarcinoma Criteria and Classification: Validation and Interobserver Reproducibility.

Authors:  Anjelica Hodgson; Kay J Park; Bojana Djordjevic; Brooke E Howitt; Marisa R Nucci; Esther Oliva; Simona Stolnicu; Bin Xu; Robert A Soslow; Carlos Parra-Herran
Journal:  Am J Surg Pathol       Date:  2019-01       Impact factor: 6.394

7.  Mesonephric adenocarcinoma of the uterine cervix with rare lung metastases: A case report and review of the literature.

Authors:  Li-Li Jiang; De-Ming Tong; Zi-Yi Feng; Kui-Ran Liu
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

8.  Female adnexal tumors of probable Wolffian origin: morphological, immunohistochemical, and molecular analysis of 15 cases.

Authors:  Jennifer A Bennett; Lauren L Ritterhouse; Larissa V Furtado; Ricardo R Lastra; Anna Pesci; Jordan M Newell; Eike Burandt; Loes Kooreman; Koen Van de Vijver; Thomas Krausz; Ana Felix; Gian Franco Zannoni; Robert H Young; Esther Oliva
Journal:  Mod Pathol       Date:  2019-10-07       Impact factor: 7.842

Review 9.  Tissue-based Immunohistochemical Biomarker Accuracy in the Diagnosis of Malignant Glandular Lesions of the Uterine Cervix: A Systematic Review of the Literature and Meta-Analysis.

Authors:  Sandra Lee; Marianne S Rose; Vikrant V Sahasrabuddhe; Rachel Zhao; Máire A Duggan
Journal:  Int J Gynecol Pathol       Date:  2017-07       Impact factor: 2.762

10.  Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.

Authors:  Jelena Mirkovic; Lynette M Sholl; Elizabeth Garcia; Neal Lindeman; Laura MacConaill; Michelle Hirsch; Paola Dal Cin; Melissa Gorman; Justine A Barletta; Marisa R Nucci; W Glenn McCluggage; Brooke E Howitt
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.